Special Issue

T Cell Responses in SARS-CoV-2

Message from the Guest Editors

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is affecting the world's population in manifold ways, and we are still searching for solutions in order to reach the stage of controlled endemicity. So far, research and vaccine development has largely focused on spike glycoprotein-specific antibody induction and stability, which is critical to avoid infection and limit the spread of SARS-CoV-2. However, increasing global immunity driving the evolution of escape mutations is increasing the importance of a broad, robust T-cell memory-based immunity. The development of second-generation vaccines will require an extensive knowledge of T-cell responses, including type and conservation of T-cell epitopes, pre-existing immunity as well as induction, compartmentalization, stability, and phenotype of overall T cell responses.

Guest Editors

Dr. Kilian Schober

Mikrobiologisches Institut – Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen, Friedrich- Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

Dr. Lucie Loyal

1. Si-M / "Der Simulierte Mensch" a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany
2. Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Center for Regenerative Therapies, Berlin (BCRT), Germany

Deadline for manuscript submissions

closed (31 December 2022)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/107147

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/vaccines

MDPI

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).